Conditions: Hepatitis C
Keywords: Peginterferon Platelets Ribavirin Hepatitis C-related thrombocytopenia Thrombocytopenia Hepatitis C Thrombopoietin
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 27
Healthy volunteers: no

Brief summary:
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.

Detailed description:

Arms:
arm 1: Open-label eltrombopag with dose titrations to support adequate platelet counts.

Interventions: intervention 1: Eltrombopag intervention 2: Antiviral therapy
Intervention descriptions: intervention 1: Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose. intervention 2: Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.

Protocol document: